Cargando…

Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?

We retrospectively analysed the data files of 171 adults and 87 children/adolescents with severe haemophilia, except for 14 patients (moderate; minor) (1), to develop a global population pharmacokinetic (PK) model for eight factors VIII (FVIII) that could estimate individual PK parameters for target...

Descripción completa

Detalles Bibliográficos
Autores principales:	Allard, Quentin, Djerada, Zoubir, Pouplard, Claire, Repessé, Yohann, Desprez, Dominique, Galinat, Hubert, Frotscher, Birgit, Berger, Claire, Harroche, Annie, Ryman, Anne, Flaujac, Claire, Chamouni, Pierre, Guillet, Benoît, Volot, Fabienne, Szymezak, Jean, Nguyen, Philippe, Cazaubon, Yoann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7238177/ https://www.ncbi.nlm.nih.gov/pubmed/32326156 http://dx.doi.org/10.3390/pharmaceutics12040380

Ejemplares similares

A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis
por: Guillet, Benoit, et al.
Publicado: (2023)

Population Pharmacokinetics Modelling and Simulation of Mitotane in Patients with Adrenocortical Carcinoma: An Individualized Dose Regimen to Target All Patients at Three Months?
por: Cazaubon, Yoann, et al.
Publicado: (2019)

Quantification of 15 Antibiotics Widely Used in the Critical Care Unit with a LC-MS/MS System: An Easy Method to Perform a Daily Therapeutic Drug Monitoring
por: Feliu, Catherine, et al.
Publicado: (2021)

Development and Validation of a Non-Targeted Screening Method for Most Psychoactive, Analgesic, Anaesthetic, Anti-Diabetic, Anti-Coagulant and Anti-Hypertensive Drugs in Human Whole Blood and Plasma Using High-Resolution Mass Spectrometry
por: Feliu, Catherine, et al.
Publicado: (2023)

Effectiveness of long‐term prophylaxis using pdFVIII/VWF concentrate in patients with inherited von Willebrand disease
por: Rugeri, Lucia, et al.
Publicado: (2022)

Complementary Role of P2 and Adenosine Receptors in ATP Induced-Anti-Apoptotic Effects Against Hypoxic Injury of HUVECs
por: Feliu, Catherine, et al.
Publicado: (2019)

Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study
por: Goudemand, Jenny, et al.
Publicado: (2020)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab
por: Konecki, Celine, et al.
Publicado: (2021)

P1672: OCCUPATIONAL INTEGRATION OF ADULTS WITH SEVERE HAEMOPHILIA (INTHEMO): A STUDY BASED ON THE FRANCECOAG REGISTRY
por: Nguyen, Ngoc Anh Thu, et al.
Publicado: (2023)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study
por: Resseguier, Noémie, et al.
Publicado: (2018)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia
por: van Moort, Iris, et al.
Publicado: (2021)

Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia
por: Turecek, Peter L., et al.
Publicado: (2020)

Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Health-related quality of life of moderate and severe haemophilia patients: Results of the haemophilia-specific quality of life index in Korea
por: Baek, Hee Jo, et al.
Publicado: (2020)

Identification of a novel mutation in the factor VIII gene causing severe haemophilia A
por: Nissen, S. K., et al.
Publicado: (2018)

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A
por: Persson, Sofie, et al.
Publicado: (2022)

Ex vivo factor VIII‐modified proliferating human hepatocytes therapy for haemophilia A
por: Zhang, Kun, et al.
Publicado: (2023)

Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures
por: Kocher, Florian, et al.
Publicado: (2021)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
por: Du, Lily M., et al.
Publicado: (2013)

Clinical Application of Factor VIII:C to VWF:Ag Ratio for the Screening of Haemophilia A Carriers
por: Yoo, Ki-Young, et al.
Publicado: (2022)

Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians
por: Borchiellini, Alessandra, et al.
Publicado: (2021)

The Effect of Yoga on the Quality of Life in the Children and Adolescents with Haemophilia
por: Beheshtipoor, Noushin, et al.
Publicado: (2015)

Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
por: Lorenzoni, Valentina, et al.
Publicado: (2018)

Heparin-induced Thrombocytopenia Diagnosis: A Retrospective Study Comparing Heparin-induced Platelet Activation Test to (14) C-serotonin Release Assay
por: Gonthier, Marie-Caroline, et al.
Publicado: (2021)

Successful Long Term Eradication of Factor VIII Inhibitor in Patients with Acquired Haemophilia A in Saudi Arabia
por: Zaher, Galila, et al.
Publicado: (2012)

Successful transfemoral prosthesis in a patient with haemophilia A and factor VIII inhibitors: A case report
por: Chao, Ta-Chung, et al.
Publicado: (2023)

Surgical outcomes in patients with haemophilia A or B receiving extended half‐life recombinant factor VIII and IX Fc fusion proteins: Real‐world experience in the Nordic countries
por: Lehtinen, Anna‐Elina, et al.
Publicado: (2022)

Acquired haemophilia A diagnosed during pregnancy
por: Ejaz, Ayesha, et al.
Publicado: (2021)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients
por: van Moort, Iris, et al.
Publicado: (2020)

Comparative Evaluation of Four Commercially Available Immunoassays for Therapeutic Drug Monitoring of Infliximab and Adalimumab
por: Rissel, Florian, et al.
Publicado: (2023)

Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data)
por: Romanová, Gabriela, et al.
Publicado: (2023)

PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia
por: Vayne, Caroline, et al.
Publicado: (2021)

A Novel Missense Mutation, E1623G, in the Human Factor VIII Gene Associated With Moderate Haemophilia A
por: Onsori, Habib, et al.
Publicado: (2014)

Influence of blood group, von Willebrand factor levels, and age on factor VIII levels in non‐severe haemophilia A
por: Rejtő, Judit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_38rk1pt5u4cui3e7lj1ct3jjjr